Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 2Neoplasm Metastasis 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Metastatic Solid Tumors 1Malignant Solid Tumour 1Glioblastoma 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

toripalimab 6Injections 4tislelizumab 3sintilimab 3pembrolizumab 3cediranib 3glumetinib 2apatinib 2PM 01183 2Midazolam 2Irinotecan 2Gemcitabine 2Drug Therapy 2Digoxin 2Bupropion 2talazoparib 1spartalizumab 1sonidegib 1sitravatinib 1serabelisib 1sapanisertib 1rucaparib 1repaglinide 1penpulimab 1palbociclib 1lenvatinib 1fluzoparib 1erdafitinib 1entrectinib 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumor × DOXO-EMCH × Clear all
NCT01673438 2022-02-10

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
15 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡